ARAVIVE ($NASDAQ:ARAV) reported their second quarter FY2023 earnings results on June 30 2023. Total revenue for the period was USD 1.3 million, representing a year-on-year decrease of 21.6%, while net income was USD 18.0 million, showing an increase of 197.5%.
On Monday, ARAVIVE reported strong earnings for Q2 FY2023. The stock opened at $0.2 and closed at the same price, representing a 6.6% drop from the prior closing price of $0.2. This increase was driven by strong product sales, as well as continued growth in ARAVIVE’s core businesses of biopharmaceuticals and healthcare services. As it continues to focus on its core business of biopharmaceuticals and healthcare services, ARAVIVE is well-positioned to capitalize on future growth opportunities. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Aravive. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aravive. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aravive. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Aravive are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have conducted an in-depth analysis of ARAVIVE‘s fundamentals. We have detected three risk warnings in the income sheet, balance sheet and cashflow statement. Register with us to find out more about these warnings and make an informed decision about your investments. Our comprehensive analysis will help you assess the strength of ARAVIVE’s fundamentals and make an educated decision regarding your investments. At GoodWhale, we strive to provide our customers with the best possible advice and guidance when it comes to their investments. With our comprehensive analysis and risk rating system, we ensure that our customers are well-equipped to make the smartest decisions for their investments. Register with us today to get the most out of your investments. More…
Risk Rating Analysis
Star Chart Analysis
In the same industry, Aravive competes with other companies such as Reata Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, and Talaris Therapeutics Inc, among others. All of these companies strive to create treatments and solutions for diseases in order to improve the lives of those affected by them.
– Reata Pharmaceuticals Inc ($NASDAQ:RETA)
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious, life-threatening diseases. The company has a market capitalization of 3.3 billion dollars as of 2023 and a Return on Equity of 551.98%. Reata’s products in development target serious conditions such as pulmonary diseases, dermatological diseases, neurological disorders, and cancer. The company’s strong Return on Equity of 551.98% shows that the company is making efficient use of its resources and is heading in the right direction towards long-term profits and success.
– Day One Biopharmaceuticals Inc ($NASDAQ:DAWN)
Day One Biopharmaceuticals Inc is a biotechnology company focused on developing innovative treatments for cancer and other diseases. The company has a market cap of 1.32 billion dollars as of 2023, making it a mid-cap stock. Its Return on Equity (ROE) is -26.42%, which suggests that the company has not been able to generate good profitability over the last year. This could be due to high investment costs, operational inefficiencies, or a combination of other factors. Regardless, Day One Biopharmaceuticals Inc remains dedicated to developing cutting-edge treatments for life-threatening illnesses.
– Talaris Therapeutics Inc ($NASDAQ:TALS)
Talaris Therapeutics Inc is a biopharmaceutical company focused on developing treatments for rare diseases. The company currently has a market cap of 76.74M, indicating that it has a lower than average market capitalization compared to other companies. This is likely due to the company not having yet achieved significant revenue growth or profitability. Nevertheless, the company has reported a return on equity of -21.89%, indicating that it is not making much of a profit compared to other companies in the same industry. Despite this, Talaris Therapeutics continues to make progress towards developing treatments for rare diseases and has the potential to grow in the future.
Investors have been analyzing ARAVIVE‘s second quarter of FY2023 earnings results, released on June 30th 2023, with caution. Total revenue has decreased by 21.6%, yet the company managed to report a net income increase of 197.5% year over year. This healthy increase in net income has not been enough to offset the revenue decrease, as stock prices moved down following the announcement. Analysts are now watching ARAVIVE closely to see if the company can continue to deliver positive earnings results in future quarters.